Clinical Applications of Diabetes Antibody Testing
Abstract
CONTEXT: Autoantibodies to glutamate decarboxylase, islet antigen-2, insulin, and zinc transporter-8 are characteristic of type 1 diabetes. They are detectable before clinical onset and define the subgroup of patients with latent autoimmune diabetes in adults. Autoantibody assays are increasingly available to clinicians. This article reviews the prognostic significance of autoantibodies and considers the utility of diabetes antibody testing in routine clinical practice. EVIDENCE ACQUISITION: The medical literature to May 2009 was reviewed for key articles and consensus statements covering use of islet autoantibody testing for prediction and classification of diabetes and implications for therapy. EVIDENCE SYNTHESIS: Sensitive and specific glutamate decarboxylase and islet antigen-2 antibody assays are widely available, although to insulin autoantibody assays remain variable. Islet autoantibodies appear early in life, and testing for multiple antibodies identifies unaffected individuals at very high risk of type 1 diabetes with high sensitivity. This is important for research, but currently no intervention prevents or delays diabetes, and evidence of benefit from awareness of risk is weak. In non-insulin-treated diabetes, patients with autoantibodies progress to insulin requirement more rapidly, but evidence that testing benefits the individual patient is limited. Antibody testing is useful in classifying diabetes of other types. CONCLUSIONS: Islet autoantibody testing allows prediction of type 1 diabetes and definition of the latent autoimmune diabetes in adults subgroup of non-insulin-treated patients. Although useful for research, until therapies modulating the disease process become available, the benefit to individual patients is generally questionable. With a few exceptions, diabetes antibody testing does not yet have a role in routine clinical care.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Islet cell antibody measurement is an imprecise biological assay that has been superseded by the direct measurement of single antibodies.
“Islet cell antibody (ICA) measurement is no longer recommended because it is an imprecise biological assay that has been superseded by the direct measurement of single antibodies (21,22).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [21]
In “Autoantibodies, Assays, and Thresholds” (page not provided), the paper describes ICA immunofluorescence as technically demanding and difficult to standardize, and identifies individual antibodies that contribute to ICA staining. It does not say ICA measurement is no longer recommended or has been superseded; it also lists ICA as an alternative to ZnT8A among markers measured at disease onset. (LLM, conf=0.84)
Experimental — accuracy not yet measuredMuch of the understanding about the pathogenesis of type 1 diabetes derives from analysis of pancreatic specimens, serum, and peripheral-blood lymphocytes obtained from patients with the disorder.
“Much of what we understand about the pathogenesis of type 1 diabetes derives from analysis of pancreatic specimens, serum, and peripheral-blood lymphocytes obtained from patients with the disorder.53,54”
From Type 1 diabetes (2014) · cites this paper as [53]
The introductory passage under Abstract (page not provided) describes how detecting islet antibodies before diabetes onset revealed a long disease prodrome, supporting the serum-antibody part of the claim. The paper does not say that much of our understanding of pathogenesis derives from analysis of patient pancreatic specimens or peripheral-blood lymphocytes. (LLM, conf=0.78)
Experimental — accuracy not yet measuredMore than 90% of individuals with newly diagnosed type 1 diabetes have one or more of the following autoantibodies at disease onset: IAA, GADA, IA2A, and ZnT8A.
“More than 90% of individuals with newly diagnosed type 1 diabetes have one or more of the following autoantibodies at disease onset:53 those reactive to insulin (IAA), glutamic acid decarboxylase (GADA), insulinoma-associated autoantigen 2 (IA2A), and zinc transporter 8 (ZnT8A).65”
From Type 1 diabetes (2014) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Incidence of diabetes in youth in the United States
SEARCH for Diabetes in Youth Study Group*, T. W. G. F. T. (2007) · JAMA · doi:10.1001/jama.297.24.2716 · Cited by 991 · cited 1× · see citing works
“The initial publication from the SEARCH for Diabetes in Youth study reported that 21% of young people diagnosed as having type 2 diabetes had GADA, but fasting C-peptide and insulin treatment did not differ from the GADA-negative group (79).”
BackgroundEffects of insulin in relatives of patients with type 1 diabetes mellitus
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012350 · Cited by 836 · see citing works
Steffes, M. W., Sibley, S., Jackson, M., & Thomas, W. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.832 · Cited by 695 · see citing works
Effects of Oral Insulin in Relatives of Patients With Type 1 Diabetes
The Diabetes Prevention Trial-Type 1 Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1068 · Cited by 668 · see citing works
GAD treatment and insulin secretion in recent-onset type 1 diabetes
Ludvigsson, J., Faresjö, M., Hjorth, M., Axelsson, S., Chéramy, M., Pihl, M., Vaarala, O., Forsander, G., Ivarsson, S., Johansson, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804328 · Cited by 520 · see citing works
Diabetes Antibody Standardization Program: first assay proficiency evaluation
Bingley, P. J., Bonifacio, E., Mueller, P. W., & Laboratories, P. (2003) · Diabetes · doi:10.2337/diabetes.52.5.1128 · Cited by 362 · see citing works
Self-citationTörn, C., Mueller, P. W., Schlosser, M., Bonifacio, E., Bingley, P. J., & Laboratories, P. (2008) · Diabetologia · doi:10.1007/s00125-008-0967-2 · Cited by 284 · see citing works
Self-citationPredictors of postpartum diabetes in women with gestational diabetes mellitus
Löbner, K., Knopff, A., Baumgarten, A., Mollenhauer, U., Marienfeld, S., Garrido-Franco, M., Bonifacio, E., & Ziegler, A.-G. (2006) · Diabetes · doi:10.2337/diabetes.55.03.06.db05-0746 · Cited by 234 · see citing works
Accuracy and predictive value of classification schemes for ketosis-prone diabetes
Balasubramanyam, A., Garza, G., Rodriguez, L., Hampe, C. S., Gaur, L., Lernmark, A., & Maldonado, M. R. (2006) · Diabetes Care · doi:10.2337/dc06-0749 · Cited by 166 · see citing works
Flagged first, then by citations
Research works printed but not linked: 4
- Greenbaum CJ, Palmer JP, Kuglin B, Kolb H 1992 Insulin autoan- tibodies measured by radioimmunoassay methodology are more re- lated to insulin dependent diabetes mellitus than those measured by enzyme-linked immunosorbent assay: results of the Fourth Interna- tional Workshop on the Standardization of Insulin Autoantibody Measurement. J Clin Endocrinol Metab 74:1040 -1044
- Siljander HT, Simell S, Hekkala A, Lähde J, Simell T, Vähäsalo P, Veijola R, Ilonen J, Simell O, Knip M 2009 Predictive characteristics of diabetes-associated autoantibodies among children with HLA- conferred disease susceptibility in the general population. Diabetes doi:10.2337/db08-1305 · DOI
- Lampasona V, Petrone A, Tiberti C, Capizzi M, Spoletini M, di Pietro S, Songini M, Bonicchio S, Giorgino F, Bonifacio E, Bosi E, Buzzetti R, for the NIRAD Study Group 2009 Zinc Transporter 8 antibodies complement GAD and IA-2 antibodies in the identifica- tion and characterization of adult-onset autoimmune diabetes: NIRAD 4. Diabetes Care doi:10.2337/dc08-2305 · DOI
- Shepherd M, Pearson ER, Houghton J, Salt G, Ellard S, Hattersley AT 2003 No deterioration in glycemic control in HNF-1␣ maturity- onset diabetes of the young following transfer from long-term in- sulin to sulphonylureas. Diabetes Care 26:3191-3192
Cited by
Sorted by citations
Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60591-7 · Cited by 2,713 · see citing works
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699 · see citing works
Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors
Stamatouli, A. M., Quandt, Z., Perdigoto, A. L., Clark, P. L., Kluger, H., Weiss, S. A., Gettinger, S., Sznol, M., Young, A., Rushakoff, R., et al. (2018) · Diabetes · doi:10.2337/dbi18-0002 · Cited by 590 · see citing works
Todd, J. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.04.001 · Cited by 560 · see citing works
Thomas, N. J., Jones, S. E., Weedon, M. N., Shields, B. M., Oram, R. A., & Hattersley, A. T. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30362-5 · Cited by 417 · see citing works
Sharp, S. A., Rich, S. S., Wood, A. R., Jones, S. E., Beaumont, R. N., Harrison, J. W., Schneider, D. A., Locke, J. M., Tyrrell, J., Weedon, M. N., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1785 · Cited by 366 · see citing works
Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group, Krischer, J. P., Schatz, D. A., Bundy, B., Skyler, J. S., & Greenbaum, C. J. (2017) · JAMA · doi:10.1001/jama.2017.17070 · Cited by 214 · see citing works
Early prediction of autoimmune (type 1) diabetes.
Regnell, S. E., & Lernmark, Å. (2017) · Diabetologia · doi:10.1007/s00125-017-4308-1 · Cited by 195 · see citing works
Thomas, N. J., Lynam, A. L., Hill, A. V., Weedon, M. N., Shields, B. M., Oram, R. A., McDonald, T. J., Hattersley, A. T., & Jones, A. G. (2019) · Diabetologia · doi:10.1007/s00125-019-4863-8 · Cited by 183 · see citing works
Shields, B. M., Shepherd, M., Hudson, M., McDonald, T. J., Colclough, K., Peters, J., Knight, B., Hyde, C., Ellard, S., Pearson, E. R., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0224 · Cited by 151 · see citing works
Jones, A. G., McDonald, T. J., Shields, B. M., Hagopian, W., & Hattersley, A. T. (2021) · Diabetes Care · doi:10.2337/dc20-2834 · Cited by 122 · see citing works
Autoimmune endocrine dysfunctions associated with cancer immunotherapies
Ferrari, S. M., Fallahi, P., Elia, G., Ragusa, F., Ruffilli, I., Patrizio, A., Galdiero, M. R., Baldini, E., Ulisse, S., Marone, G., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102560 · Cited by 107 · see citing works
Yu, L., Boulware, D. C., Beam, C. A., Hutton, J. C., Wenzlau, J. M., Greenbaum, C. J., Bingley, P. J., Krischer, J. P., Sosenko, J. M., Skyler, J. S., et al. (2012) · Diabetes Care · doi:10.2337/dc11-2081 · Cited by 104 · see citing works
Self-citationAchenbach, P., Hummel, M., Thümer, L., Boerschmann, H., Höfelmann, D., & Ziegler, A. G. (2013) · Diabetologia · doi:10.1007/s00125-013-2896-y · Cited by 76 · see citing works
Immunotherapy to treat malignancy in patients with pre-existing autoimmunity
Boland, P., Pavlick, A. C., Weber, J., & Sandigursky, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000356 · Cited by 50 · see citing works
Cantú-Rodríguez, O. G., Lavalle-González, F., Herrera-Rojas, M. Á., Jaime-Pérez, J. C., Hawing-Zárate, J. Á., Gutiérrez-Aguirre, C. H., Mancias-Guerra, C., González-Llano, O., Zapata-Garrido, A., Villarreal-Pérez, J. Z., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2776 · Cited by 39 · see citing works
- Authors
- Bingley, P. J.
- Affiliations
- Southmead Hospital (GB)
- Corresponding author
- Bingley, Polly J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2010-01
- Volume
- 95
- Issue
- 1
- Pages
- 25-33
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2059471307
- Cited by
- 278
- References
- 9
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 22 · 2023: 15 · 2022: 24 · 2021: 13 · 2020: 17 · 2019: 21 · 2018: 18 · 2017: 18 · 2016: 15 · 2015: 11 · 2014: 14 · 2013: 21 · 2012: 17
- FWCI
- 9.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Explore Bristol Research (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- islet autoantibodies, type 1 diabetes, latent autoimmune diabetes in adults, glutamic acid decarboxylase antibodies, insulin autoantibodies, zinc transporter 8 antibodies, diabetes prediction, diabetes classification, non-insulin-treated diabetes
- MeSH terms
- Autoantibodies, Diabetes Mellitus, Humans, Immunologic Tests, Mass Screening, Prognosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
